Truist raised the firm’s price target on Humana to $590 from $560 and keeps a Hold rating on the shares as part of a broader research note on Health Care names. The firm remains bullish across much of Health Care Services given attractive core demand, the ongoing shift to value, reasonable valuations and impacts on the system over the past few years that have further tipped the playing field in favor of scaled and high quality providers, even though it still sees some macro challenges around a potential recession, available labor, and inflation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HUM:
- Humana price target raised to $637 from $620 at Morgan Stanley
- Morgan Stanley says Humana could trade up by mid-single digits on final MA rates
- Final Medicare Advantage rates positive for managed care, says JPMorgan
- Ohio AG Yost sues Express Scripts, Prime Therapeutics over drug price fixing
- Cigna, Humana accused of price fixing by Ohio attorney general, WSJ reports